Arcturus Therapeutics Holdings Inc.
ARCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768224
No open-market purchases or sales by Arcturus Therapeutics Holdings Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +12 vs. previous quarter
- 135
- 13F valueReported value at the end of Q2 2026
- $167.9M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ARCT, Q2 2026
1 superinvestor reports holding Arcturus Therapeutics Holdings Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.1%
Arcturus Therapeutics Holdings Inc.'s share of the portfolio
- Shares
- 2,901,635
- Value
- $19.5M
Latest insider trades
Open-market purchases and sales by Arcturus Therapeutics Holdings Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 (view filing) | Aug 15 | 5 days | Sassine AndyChief Financial Officer | PPurchase | +1.24K | $16.56 | +$20.5K | +0.6%221.8K after | Amended |
| Oct 16, 2024 (view filing) | Oct 15 | 1 day | Chivukula PadChief Scientific Officer & COO | SSale | −12.0K | $20.76 | −$249.1K | −2.7%435.3K after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 12 | 2 days | Sassine AndyChief Financial Officer | SSale | −50.0K | $32.03 | −$1.60M | −18.5%220.5K after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −114 | $45.00 | −$5.13K | 0.0%447.3K after | 10b5-1 |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Chivukula PadChief Scientific Officer & COO | SSale | −26.0K | $40.01 | −$1.04M | −5.5%447.4K after | 10b5-1 |
| Mar 27, 2024 (view filing) | Mar 25 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −17.4K | $35.02 | −$610.6K | −3.6%473.4K after | 10b5-1 |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −8.56K | $35.01 | −$299.9K | −1.7%490.9K after | 10b5-1 |
| Nov 3, 2023 (view filing) | Nov 1 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $18.72 | −$93.6K | −1.0%499.4K after | 10b5-1 |
| Oct 4, 2023 (view filing) | Oct 2 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $25.61 | −$128.1K | −1.0%504.4K after | 10b5-1 |
| Sep 5, 2023 (view filing) | Sep 1 | 4 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $31.45 | −$157.3K | −1.0%509.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Arcturus Therapeutics Holdings Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 3,303,640 | $22.2M | 0.03% | 00.0% | Unchanged |
| ARK Investment Management LLCSuperinvestorARK Invest | 2,901,635 | $19.5M | 0.13% | +132,117+4.8% | Added |
| BlackRock, Inc. | 2,614,012 | $17.6M | 0.00% | +7310.0% | Added |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,963,123 | $13.2M | 0.01% | −325,812−14.2% | Reduced |
| Nikko Asset Management Americas, Inc. | 1,960,458 | $13.1M | 0.17% | −328,477−14.4% | Reduced |
| Vanguard Capital Management LLC | 1,114,956 | $7.49M | 0.00% | +7,936+0.7% | Added |
| Two Sigma Investments, LP | 1,091,137 | $7.33M | 0.01% | +9,353+0.9% | Added |
| Vanguard Portfolio Management LLC | 951,575 | $6.39M | 0.00% | −26,347−2.7% | Reduced |
| Geode Capital Management, LLC | 693,660 | $4.66M | 0.00% | +32,732+5.0% | Added |
| AQR Capital Management LLC | 675,014 | $4.54M | 0.00% | +513,736+318.5% | Added |